Vxbiosciences, Inc.

Vxbiosciences, Inc. is an innovative therapeutic company specializing in the development of cutting-edge antiviral technologies, including lipid nanoparticle formulations and autonomous, co-evolving therapeutic molecular parasites. The company has secured significant federal funding for its work on combating viral threats and overcoming drug resistance challenges. Registered to receive awards from the U.S. federal government since May 2020, Vxbiosciences has been awarded both federal contracts and grants, demonstrating its expertise in research and development of novel antiviral therapies.

Through federal contracts, Vxbiosciences has engaged in critical research and development efforts focused on addressing urgent viral threats. A recent $176,056 firm fixed-price purchase order was awarded by the Defense Health Agency for the development of Dengue Tip Candidate Antivirals, supporting research at the Walter Reed Army Institute of Research. This award, not set aside for any specific business category, highlights the company's capabilities in developing innovative solutions for tropical diseases. Additionally, Vxbiosciences received a contract from the Office of the Assistant Secretary for Preparedness and Response for the R&D of pan-coronavirus intranasal delivery technology, further demonstrating its commitment to addressing emerging viral threats.

Vxbiosciences has also secured substantial federal grant funding for its groundbreaking research. A $300,000 project grant from the National Institute of Allergy and Infectious Diseases supports the development of a first-in-class antiviral therapeutic targeting cytomegalovirus (CMV) infections in immunocompromised patients. This project aims to establish in vivo efficacy and dosing of a novel 'escape-resistant' nucleic-acid lipid nanoparticle antiviral and develop a GMP-grade formulation for IND-enabling toxicology studies. Another significant grant from the Office of the Director, National Institutes of Health, funds the development of autonomously deploying, co-evolving SARS-CoV-2 antivirals. This innovative approach involves engineering therapeutic molecular parasites of SARS-CoV-2 that can co-adapt and transmit among infected hosts, potentially overcoming the limitations of current static interventions. These grants underscore Vxbiosciences' role in advancing novel antiviral strategies with high barriers to resistance and potential for significant public health impact.